Skip to main content
. 2016 Apr 7;4:10.3402/jmahp.v4.30754. doi: 10.3402/jmahp.v4.30754

Fig. 3.

Fig. 3

cINHB along the drug lifetime (in the acute disease setting) accounting for the off-patent price. Solid line: cINHB under the conventional CEA approach. Dotted line: cINHB function under the proposed CEA approach. Dashed line: cINHB under a hypothetical scenario where the manufacturer captures 100% of the value of innovation during patent protection.